In conclusion, we found that Bcl-xL is responsible for TRAIL resistance in human pancreatic cancer cells and that the Bcl-2 family inhibitors, including ABT-263 and ABT-737, induce/restore the TRAIL sensitivity of pancreatic cancer cell lines both in vitro and in vivo. The gene discussed is BCL2; the disease is familial pancreatic carcinoma.